Stokes Family Office LLC Raises Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Stokes Family Office LLC grew its stake in Novo Nordisk A/S (NYSE:NVO) by 2.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,477 shares of the company’s stock after buying an additional 230 shares during the quarter. Stokes Family Office LLC’s holdings in Novo Nordisk A/S were worth $729,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Marco Investment Management LLC increased its position in Novo Nordisk A/S by 1.5% in the third quarter. Marco Investment Management LLC now owns 6,702 shares of the company’s stock worth $798,000 after buying an additional 100 shares in the last quarter. Menard Financial Group LLC increased its position in Novo Nordisk A/S by 0.8% in the third quarter. Menard Financial Group LLC now owns 12,283 shares of the company’s stock worth $1,463,000 after buying an additional 102 shares in the last quarter. Optimist Retirement Group LLC increased its position in Novo Nordisk A/S by 4.3% in the third quarter. Optimist Retirement Group LLC now owns 2,747 shares of the company’s stock worth $327,000 after buying an additional 112 shares in the last quarter. Financial Counselors Inc. increased its position in Novo Nordisk A/S by 1.1% in the third quarter. Financial Counselors Inc. now owns 11,009 shares of the company’s stock worth $1,311,000 after buying an additional 115 shares in the last quarter. Finally, M. Kulyk & Associates LLC grew its position in shares of Novo Nordisk A/S by 3.9% during the fourth quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company’s stock worth $274,000 after purchasing an additional 119 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NYSE:NVO opened at $80.95 on Wednesday. The firm has a market capitalization of $363.28 billion, a price-to-earnings ratio of 24.61, a PEG ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a 1 year low of $73.80 and a 1 year high of $148.15. The business has a 50 day simple moving average of $83.81 and a 200-day simple moving average of $101.98. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 47.72%.

Analyst Ratings Changes

Several research firms have weighed in on NVO. Morgan Stanley began coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. BMO Capital Markets cut their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 13th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.